Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 88.25
-1.75 (-1.94%)
May 11, 2026, 4:08 PM HKT
Innovent Biologics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 813.57 | -94.63 | -1,028 | -2,179 | -2,729 |
Depreciation & Amortization | 596.84 | 417.46 | 310.22 | 276.79 | 202.17 |
Other Amortization | 4.48 | 2.31 | 74.89 | 42.64 | 2.58 |
Loss (Gain) From Sale of Assets | 0.57 | 22.99 | 0.95 | -0.06 | 0.71 |
Asset Writedown & Restructuring Costs | 31.52 | 632.57 | 115.36 | - | - |
Loss (Gain) From Sale of Investments | -4.56 | -179.03 | -30.81 | -5.1 | -125.02 |
Loss (Gain) on Equity Investments | 96.79 | 41.01 | - | - | - |
Stock-Based Compensation | 662.7 | 556.52 | 574.2 | 469.49 | 501.57 |
Other Operating Activities | -145.43 | -515.93 | -272.47 | -833.19 | 213.88 |
Change in Accounts Receivable | -529.43 | -178.52 | -430.62 | 393.14 | -493.03 |
Change in Inventory | -451.46 | 180.63 | 358.95 | -105.39 | -643.28 |
Change in Accounts Payable | 136.91 | -14.87 | 46.93 | 130.57 | 74.43 |
Change in Unearned Revenue | 7,661 | -31.19 | -138.63 | 205.04 | 105.43 |
Change in Other Net Operating Assets | 1,127 | 447.71 | 566.77 | -313.45 | 864.46 |
Operating Cash Flow | 10,001 | 1,287 | 147.81 | -1,919 | -2,025 |
Operating Cash Flow Growth | 677.06% | 770.73% | - | - | - |
Capital Expenditures | -269.88 | -965.67 | -1,119 | -896.9 | -1,066 |
Sale of Property, Plant & Equipment | - | 0.27 | 0.05 | 0.19 | 0.1 |
Sale (Purchase) of Intangibles | -413.39 | -676.42 | -262.35 | -468.6 | -781.88 |
Sale (Purchase) of Real Estate | - | - | 16.23 | - | - |
Investment in Securities | -6,377 | -981.19 | -204.43 | -384.74 | -254.58 |
Other Investing Activities | 548.31 | 1,458 | 571.22 | 314.87 | -596.15 |
Investing Cash Flow | -6,512 | -1,165 | -998.66 | -1,435 | -2,698 |
Long-Term Debt Issued | 2,504 | 515.57 | 1,336 | 1,080 | 1,463 |
Long-Term Debt Repaid | -2,555 | -1,246 | -948.85 | -392.74 | -278.72 |
Net Debt Issued (Repaid) | -50.74 | -730.44 | 386.7 | 687.43 | 1,184 |
Issuance of Common Stock | 4,719 | 84.31 | 2,255 | 2,131 | 3,951 |
Other Financing Activities | 60.46 | 39.5 | -54.56 | 73.59 | -131.52 |
Financing Cash Flow | 4,728 | -606.63 | 2,587 | 2,892 | 5,003 |
Foreign Exchange Rate Adjustments | -115.59 | 12.68 | -6.88 | 118.66 | -197.14 |
Net Cash Flow | 8,102 | -472.34 | 1,730 | -343.24 | 83.23 |
Free Cash Flow | 9,731 | 321.36 | -971.58 | -2,816 | -3,090 |
Free Cash Flow Growth | 2928.12% | - | - | - | - |
Free Cash Flow Margin | 74.62% | 3.41% | -15.65% | -61.80% | -72.38% |
Free Cash Flow Per Share | 5.59 | 0.20 | -0.62 | -1.89 | -2.12 |
Cash Interest Paid | 95.24 | 122.43 | 127.61 | 104.88 | 78.83 |
Cash Income Tax Paid | 0.64 | 0.16 | -114.42 | 66.1 | 26.44 |
Levered Free Cash Flow | 3,228 | -17.42 | -907.54 | -2,475 | -2,612 |
Unlevered Free Cash Flow | 3,278 | 24.86 | -845.9 | -2,411 | -2,573 |
Change in Working Capital | 7,945 | 403.76 | 403.39 | 309.91 | -91.98 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.